Objective: We analyzed the association of 54 biomarkers from seven classes including adipokines, immune response metalloproteinases, adhesion molecules, and growth factors with prostate cancer risk adjusting for the Prostate Cancer Prevention Trial (PCPT) risk score.
Methods: A total of 123 incident prostate cancer cases and 127 age-matched controls were selected from subjects in the San Antonio Center for Biomarkers of Risk of Prostate Cancer cohort study. Prediagnostic serum concentrations were measured in the sample collected at baseline using LabMAP technology. The odds ratios (OR) of prostate cancer risk associated with serum concentrations of 54 markers were estimated using univariate conditional logistic regression before and after adjustment for the PCPT risk score. Two-way hierarchical unsupervised clustering techniques were used to evaluate whether the 54-marker panel distinguished cases from controls.
Results: Vascular endothelial growth factor, resistin, interleukin 1Ra (IL-1Ra), granulocyte colony-stimulating factor, matrix metalloproteinase-3, plasminogen activator inhibitor, and kallikrein-8 were statistically significantly (P < 0.05) underexpressed in prostate cancer cases, and alpha-fetoprotein was statistically significantly overexpressed in prostate cancer cases, but all had area underneath the receiver-operating characteristic curve <60%; none were statistically significant adjusting for multiple comparisons (P < 0.0008) or after adjustment for the PCPT risk score. Statistical clustering of patients by the marker panel did not distinguish a separate group of cases from controls.
Conclusions: This age-matched case-control study did not support findings of increased diagnostic potential from a 54-marker panel when compared with the conventional risk factors incorporated in the PCPT risk calculator. Future discovery of new biomarkers should always be tested and compared against conventional risk factors before applying them in clinical practice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1158/1055-9965.EPI-07-0302 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vaccine Therapies for Prostate Cancer: Current Status and Future Outlook.
Vaccines (Basel)
December 2024
Department of Urology, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200434, China.
Prostate cancer is a prevalent cancer in elderly men, and immunotherapy has emerged as a promising treatment approach in recent years. The aim of immunotherapy is to stimulate the body's immune system to target and destroy cancer cells. Cancer vaccines that are highly specific, safe, and capable of creating long-lasting immune responses are a key focus in cancer immunotherapy research.
View Article and Find Full Text PDFOptimized Synthetic Correlated Diffusion Imaging for Improving Breast Cancer Tumor Delineation.
Sensors (Basel)
December 2024
Department of Systems Design Engineering, University of Waterloo, Waterloo, ON N2L 3G1, Canada.
Breast cancer is a significant cause of death from cancer in women globally, highlighting the need for improved diagnostic imaging to enhance patient outcomes. Accurate tumor identification is essential for diagnosis, treatment, and monitoring, emphasizing the importance of advanced imaging technologies that provide detailed views of tumor characteristics and disease. Recently, a new imaging modality named synthetic correlated diffusion imaging (CDI) has been showing promise for enhanced prostate cancer delineation when compared to existing MRI imaging modalities.
View Article and Find Full Text PDFImprovement of End-of-Synthesis Radiochemical Purity of Lu-DOTA-PSMA-Ligands with Alternative Synthesis Approaches: Conversion Upswing and Side-Products Minimization.
Pharmaceutics
November 2024
State Research Center-Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, Zhivopisnaya Str., Bld. 46, 123098 Moscow, Russia.
Background: Radiochemical purity is a key criterion for the quality of radiopharmaceuticals used in clinical practice. The joint improvement of analytical methods capable of identifying related radiochemical impurities and determining the actual radiochemical purity, as well as the improvement of synthesis methods to minimize the formation of possible radiochemical impurities, is integral to the implementation of high-tech nuclear medicine procedures. PSMA-targeted radionuclide therapy with lutetium-177 has emerged as an effective treatment option for prostate cancer, and [Lu]Lu-PSMA-617 and [Lu]Lu-PSMA have achieved global recognition as viable radiopharmaceuticals.
View Article and Find Full Text PDFInvestigating the Potential Effects of 6PPDQ on Prostate Cancer Through Network Toxicology and Molecular Docking.
Toxics
December 2024
Department of Urology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing 400014, China.
(1) Background: N-(1,3-Dimethylbutyl)-N'-phenyl-p-phenylenediamine-quinone (6PPDQ), as a newly discovered environmental toxin, has been found more frequently in our living conditions. The literature reports that damage to the reproductive and cardiovascular system is associated with exposure to 6PPDQ. However, the relationship between 6PPDQ and cancer still requires more investigation.
View Article and Find Full Text PDFCurcumin and Its Potential to Target the Glycolytic Behavior of Lactate-Acclimated Prostate Carcinoma Cells with Docetaxel.
Nutrients
December 2024
Department of Biochemistry, College of Medicine, Soonchunhyang University, Cheonan 31511, Republic of Korea.
Dysregulated cellular metabolism is known to be associated with drug resistance in cancer treatment. In this study, we investigated the impact of cellular adaptation to lactic acidosis on intracellular energy metabolism and sensitivity to docetaxel in prostate carcinoma (PC) cells. The effects of curcumin and the role of hexokinase 2 (HK2) in this process were also examined.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!